NCT03042091

Brief Summary

This randomized clinical trial studies how well neomycin and metronidazole hydrochloride with or without polyethylene glycol work in reducing infection in patients undergoing elective colorectal surgery. Polyethylene glycol, may draw water from the body into the colon, flushing out the contents of the colon. Antibiotics, like neomycin and metronidazole hydrochloride, may stop bacteria from growing. It is not yet known whether it's better to give preoperative neomycin and metronidazole hydrochloride with or without polyethylene glycol in reducing surgical site infection after colorectal surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
224

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Sep 2016

Longer than P75 for early_phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 31, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 3, 2017

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
Last Updated

August 22, 2018

Status Verified

August 1, 2018

Enrollment Period

4.1 years

First QC Date

January 31, 2017

Last Update Submit

August 20, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak

    The difference in incidence of SSI (antibiotics \[ABX\] - ABX + prep) will be calculated with an upper 95% confidence bound. Exploratory analysis will consider stratum specific estimates of differences in subgroups defined by BMI and diabetes status.

    Up to 30 days post operation

Secondary Outcomes (6)

  • Incidence of post-operative clostridium difficile infection

    Up to 30 days post operation

  • Incidence of adynamic ileus

    Up to 30 days post operation

  • Incidence of cardiopulmonary complications

    Up to 30 days post operation

  • Incidence of urinary tract infection

    Up to 30 days post operation

  • Length of hospital stay

    Up to 30 days post operation

  • +1 more secondary outcomes

Study Arms (2)

Arm I (mechanical bowel prep, oral antibiotics)

ACTIVE COMPARATOR

Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Drug: Polyethylene GlycolDrug: NeomycinDrug: Metronidazole HydrochlorideProcedure: Therapeutic Conventional Surgery

Arm II (oral antibiotics)

EXPERIMENTAL

Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.

Drug: NeomycinDrug: Metronidazole HydrochlorideProcedure: Therapeutic Conventional Surgery

Interventions

Given orally

Also known as: 25322-68-3, 57859, Ethanol, Glycol, Polyethylene Glycol 400
Arm I (mechanical bowel prep, oral antibiotics)

Given orally

Also known as: 1404-04-2, Neomycin Complex
Arm I (mechanical bowel prep, oral antibiotics)Arm II (oral antibiotics)

Given orally

Also known as: 69198-10-3, Flagyl, Metro I.V., Satric
Arm I (mechanical bowel prep, oral antibiotics)Arm II (oral antibiotics)

Undergo colorectal resection

Arm I (mechanical bowel prep, oral antibiotics)Arm II (oral antibiotics)

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing ileocolic resections, partial and total colectomies, and rectal resections for neoplasm, inflammatory bowel disease, or diverticulitis
  • Subjects with the mental capacity to give informed consent

You may not qualify if:

  • Patients undergoing emergent colorectal resections
  • Patients who are decisionally-impaired and lack the mental capacity to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

RECRUITING

Related Publications (1)

  • Willis MA, Toews I, Soltau SL, Kalff JC, Meerpohl JJ, Vilz TO. Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery. Cochrane Database Syst Rev. 2023 Feb 7;2(2):CD014909. doi: 10.1002/14651858.CD014909.pub2.

Related Links

MeSH Terms

Conditions

Colorectal NeoplasmsDiverticulitisInflammatory Bowel DiseasesSurgical Wound Infection

Interventions

Polyethylene GlycolsEthanolGlycolspolyethylene glycol 400NeomycinMetronidazoleBenchmarking

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesDiverticular DiseasesGastroenteritisWound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ethylene GlycolsAlcoholsOrganic ChemicalsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgricultureAminoglycosidesGlycosidesCarbohydratesNitroimidazolesNitro CompoundsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsManagement AuditOrganization and AdministrationHealth Services AdministrationProgram EvaluationQuality of Health CareQuality Assurance, Health CareHealth Care Quality, Access, and EvaluationHealth Care Evaluation Mechanisms

Study Officials

  • Benjamin Phillips, MD

    Thomas Jefferson University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Benjamin Phillips, MD

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 31, 2017

First Posted

February 3, 2017

Study Start

September 1, 2016

Primary Completion

October 1, 2020

Study Completion

October 1, 2021

Last Updated

August 22, 2018

Record last verified: 2018-08

Locations